This company listing is no longer active
3D Medicines Inkomsten in het verleden
Verleden criteriumcontroles 0/6
3D Medicines has been growing earnings at an average annual rate of 18.2%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been declining at an average rate of 31.4% per year.
Belangrijke informatie
18.2%
Groei van de winst
65.0%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 11.0% |
| Inkomstengroei | -31.4% |
| Rendement op eigen vermogen | -62.9% |
| Nettomarge | -92.0% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe 3D Medicines geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 489 | -450 | 450 | 359 |
| 31 Mar 24 | 562 | -487 | 523 | 392 |
| 31 Dec 23 | 635 | -525 | 596 | 425 |
| 30 Sep 23 | 674 | -710 | 605 | 377 |
| 30 Jun 23 | 713 | -894 | 614 | 329 |
| 31 Mar 23 | 640 | -959 | 557 | 340 |
| 31 Dec 22 | 567 | -1,024 | 501 | 351 |
| 31 Dec 21 | 60 | -1,434 | 194 | 371 |
Kwaliteitswinsten: 1244 is currently unprofitable.
Groeiende winstmarge: 1244 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 1244 is unprofitable, but has reduced losses over the past 5 years at a rate of 18.2% per year.
Versnelling van de groei: Unable to compare 1244's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 1244 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (14.7%).
Rendement op eigen vermogen
Hoge ROE: 1244 has a negative Return on Equity (-62.93%), as it is currently unprofitable.